Published in Cancer Weekly, February 27th, 2007
GS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's cancer cells.
"B-cell chronic lymphocytic leukemia is the most common adult leukemia in the Western hemisphere, yet there is no broadly applicable standard treatment with the promise to cure for this condition. Therefore, it is important to evaluate new treatment modalities...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.